EGFR and non-small cell lung carcinoma: Gefitinib, erlotinib, osimertinib, and afatinib are among the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved by the Food and Drug Administration for the treatment of metastatic NSCLC.